USFDA Grants VAI Classification to Aurobindo Pharma's Telangana Facility
Loading more articles...
Aurobindo Pharma's Apitoria Unit Gets USFDA VAI Classification, Inspection Closed
C
CNBC TV18•20-03-2026, 11:04
Aurobindo Pharma's Apitoria Unit Gets USFDA VAI Classification, Inspection Closed
•Aurobindo Pharma's subsidiary, Apitoria Pharma Pvt Ltd, received a 'Voluntary Action Indicated' (VAI) classification from the USFDA for its Unit-V manufacturing facility in Telangana.
•The USFDA inspected the API manufacturing facility from December 1 to December 12, 2025, issuing a Form 483 with three observations.
•The VAI classification means the inspection is closed and observations do not warrant regulatory action by the USFDA.
•This development follows another subsidiary, Eugia Pharma Specialities Ltd, receiving an 'Official Action Indicated' (OAI) classification earlier.
•Aurobindo Pharma reported a 7.5% YoY net profit increase to ₹909.8 crore and an 8.4% YoY revenue rise to ₹8,646 crore for the December quarter.